Cargando…

Neuropsychiatric Disturbances in Alzheimer’s Disease: What Have We Learned from Neuropathological Studies?

Neuropsychiatric symptoms (NPS) are an integral part of the dementia syndrome and were therefore recently included in the core diagnostic criteria of dementia. The near universal prevalence of NPS in Alzheimer’s disease (AD), combined with their disabling effects on patients and caregivers, is contr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Van Dam, Debby, Vermeiren, Yannick, Dekker, Alain D., Naudé, Petrus J.W., De Deyn, Peter P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bentham Science Publishers 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070416/ https://www.ncbi.nlm.nih.gov/pubmed/27137218 http://dx.doi.org/10.2174/1567205013666160502123607

Ejemplares similares

Neutrophil Gelatinase-Associated Lipocalin and its Receptors in Alzheimer’s Disease (AD) Brain Regions: Differential Findings in AD with and without Depression
por: Dekens, Doortje W., et al.
Publicado: (2016)

The monoaminergic footprint of depression and psychosis in dementia with Lewy bodies compared to Alzheimer’s disease
por: Vermeiren, Yannick, et al.
Publicado: (2015)

A TNF receptor 2 agonist ameliorates neuropathology and improves cognition in an Alzheimer’s disease mouse model
por: Ortí-Casañ, Natalia, et al.
Publicado: (2022)

Cerebrospinal fluid and serum MHPG improve Alzheimer's disease versus dementia with Lewy bodies differential diagnosis
por: Janssens, Jana, et al.
Publicado: (2018)

Serotonergic Dysfunction in Amyotrophic Lateral Sclerosis and Parkinson's Disease: Similar Mechanisms, Dissimilar Outcomes
por: Vermeiren, Yannick, et al.
Publicado: (2018)

Plasma 5‐HIAA activity indicative of serotonergic disturbances in cognitively impaired, elderly patients experiencing postoperative delirium
por: Heylen, Annelies, et al.
Publicado: (2022)

Monoaminergic impairment in Down syndrome with Alzheimer's disease compared to early-onset Alzheimer's disease
por: Dekker, Alain D., et al.
Publicado: (2017)

Alzheimer's Type Neuropathological Changes in a Patient with Depression and Anxiety: A Case Report and Literature Review of Neuropathological Correlates of Neuropsychiatric Symptoms in Alzheimer's Disease
por: Das, Sumit
Publicado: (2023)

Behavioral and Neuropathological Phenotyping of the Tau58/2 and Tau58/4 Transgenic Mouse Models for FTDP-17
por: Van Dam, Debby, et al.
Publicado: (2023)

Possible Neuropathology of Sleep Disturbance Linking to Alzheimer’s Disease: Astrocytic and Microglial Roles
por: Xiao, Shu-Yun, et al.
Publicado: (2022)

Brain Kynurenine Pathway Metabolite Levels May Reflect Extent of Neuroinflammation in ALS, FTD and Early Onset AD
por: Heylen, Annelies, et al.
Publicado: (2023)

APOE ε4, Alzheimer’s disease neuropathology and sleep disturbance, in individuals with and without dementia
por: Blackman, Jonathan, et al.
Publicado: (2022)

What have we learned?
por: Rodgers, Peter, et al.
Publicado: (2021)

Targeting TNFR2 as a Novel Therapeutic Strategy for Alzheimer’s Disease
por: Ortí-Casañ, Natalia, et al.
Publicado: (2019)

Aging rather than aneuploidy affects monoamine neurotransmitters in brain regions of Down syndrome mouse models
por: Dekker, Alain D., et al.
Publicado: (2017)

Neutrinos, what we have learned about them and what we have learned using them
por: Steinberger, J
Publicado: (2013)

Increased Cerebrospinal Fluid Production as a Possible Mechanism Underlying Caffeine's Protective Effect against Alzheimer's Disease
por: Wostyn, Peter, et al.
Publicado: (2011)

Psychological Interventions for Dementia Caregivers: What We Have Achieved, What We Have Learned
por: Cheng, Sheung-Tak, et al.
Publicado: (2019)

GOAL: What Have We Learned?
por: Leek, Timothy K Vander
Publicado: (2005)

What have we learned on mesons?
por: Moebes, J P
Publicado: (1972)

SARS: What have we learned?
Publicado: (2003)

Neuropathology of FMR1-premutation carriers presenting with dementia and neuropsychiatric symptoms
por: Dijkstra, Anke A, et al.
Publicado: (2021)

Neuropsychiatric disturbances in atypical parkinsonian disorders
por: Belvisi, Daniele, et al.
Publicado: (2018)

PTH Assays: Understanding What We Have and Forecasting What We Will Have
por: Vieira, Jose Gilberto H.
Publicado: (2012)

Treating transgenic Alzheimer mice with a β-secretase inhibitor, what have we learned?
por: Tang, Jordan, et al.
Publicado: (2011)

Lipocalin 2 contributes to brain iron dysregulation but does not affect cognition, plaque load, and glial activation in the J20 Alzheimer mouse model
por: Dekens, Doortje W., et al.
Publicado: (2018)

The neuropathological diagnosis of Alzheimer’s disease
por: DeTure, Michael A., et al.
Publicado: (2019)

What have we learned from LEP?
Publicado: (2001)

What have we learned from LEP?
Publicado: (2001)

What have we learned from LEP?
por: Ellis, Jonathan Richard
Publicado: (2001)

Genetics of Obesity: What have we Learned?
por: Choquet, Hélène, et al.
Publicado: (2011)

Higgs sector: What we have learned
por: Fiorini, Luca
Publicado: (2020)

Phage Therapy: What Have We Learned?
por: Górski, Andrzej, et al.
Publicado: (2018)

COVID-19: what have we learned?
por: Ho, Yeh-Li, et al.
Publicado: (2020)

Endometriosis and Reproduction: What We Have Learned
por: Garcia-Fernandez, Jaime, et al.
Publicado: (2020)

COVID-19: What have we learned?
por: Rafalowski, Chaim, et al.
Publicado: (2022)

Orthopaedic infections: what have we learned?
por: Lee, Christopher, et al.
Publicado: (2023)

Cerebrospinal fluid biomarkers for Alzheimer's disease in Down syndrome
por: Dekker, Alain D., et al.
Publicado: (2017)

Neuropsychiatric Disorders and COVID-19: What We Know So Far
por: Majolo, Fernanda, et al.
Publicado: (2021)

MicroRNAs and cancer: what we know and what we still have to learn
por: Calin, George A
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_4ota854bl1joklmtrjln9jfgm6